These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 36447254)
1. Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism. Ding Y; Gao S; Zheng J; Chen X Cancer Metab; 2022 Nov; 10(1):20. PubMed ID: 36447254 [TBL] [Abstract][Full Text] [Related]
2. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. Xu J; Xu Y; Ye G; Qiu J J Chemother; 2023 Oct; 35(6):527-538. PubMed ID: 36548909 [TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway. Hu J; Huang L; Ding Q; Lv J; Chen Z Cell Biol Int; 2022 Feb; 46(2):173-184. PubMed ID: 34658120 [TBL] [Abstract][Full Text] [Related]
4. LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis. Cui Z; Wang Q; Deng MH; Han QL Cancer Biomark; 2022; 34(1):41-53. PubMed ID: 34542064 [TBL] [Abstract][Full Text] [Related]
5. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p. Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791 [TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis. Gao SJ; Ren SN; Liu YT; Yan HW; Chen XB Mol Ther Oncolytics; 2021 Dec; 23():14-25. PubMed ID: 34589581 [TBL] [Abstract][Full Text] [Related]
7. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition. Li LQ; Pan D; Chen Q; Zhang SW; Xie DY; Zheng XL; Chen H Cell Physiol Biochem; 2018; 47(4):1533-1545. PubMed ID: 29940566 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a/LDHA axis. Shao X; Zheng X; Ma D; Liu Y; Liu G Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 33645623 [TBL] [Abstract][Full Text] [Related]
9. SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells. Xu Z; Sun Y; Wang D; Sun H; Liu X Cancer Cell Int; 2020; 20():236. PubMed ID: 32536824 [TBL] [Abstract][Full Text] [Related]
10. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p. Yu L; Chen D; Song J Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899 [TBL] [Abstract][Full Text] [Related]
11. SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p. Bao J; Zhang S; Meng Q; Qin T Neurochem Res; 2020 Apr; 45(4):825-836. PubMed ID: 31919621 [TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA SNHG16 promotes lipopolysaccharides-induced acute pneumonia in A549 cells via targeting miR-370-3p/IGF2 axis. Zhang J; Mao F; Zhao G; Wang H; Yan X; Zhang Q Int Immunopharmacol; 2020 Jan; 78():106065. PubMed ID: 31841752 [TBL] [Abstract][Full Text] [Related]
14. LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-135a and Promotes JAK2/STAT3 Signal Pathway in Gastric Cancer. Wang X; Kan J; Han J; Zhang W; Bai L; Wu H J Cancer; 2019; 10(4):1013-1022. PubMed ID: 30854107 [TBL] [Abstract][Full Text] [Related]
15. LncRNA SNHG16 induced by TFAP2A modulates glycolysis and proliferation of endometrial carcinoma through miR-490-3p/HK2 axis. Zhang G; Ma A; Jin Y; Pan G; Wang C Am J Transl Res; 2019; 11(11):7137-7145. PubMed ID: 31814916 [TBL] [Abstract][Full Text] [Related]
16. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343 [TBL] [Abstract][Full Text] [Related]
17. Silencing of LncRNA SNHG16 Downregulates Cyclin D1 (CCND1) to Abrogate Malignant Phenotypes in Oral Squamous Cell Carcinoma (OSCC) Through Upregulating miR-17-5p. Wang Q; Han J; Xu P; Jian X; Huang X; Liu D Cancer Manag Res; 2021; 13():1831-1841. PubMed ID: 33654431 [TBL] [Abstract][Full Text] [Related]
18. LncRNA SNHG16 drives proliferation, migration, and invasion of hemangioma endothelial cell through modulation of miR-520d-3p/STAT3 axis. Zhao W; Fu H; Zhang S; Sun S; Liu Y Cancer Med; 2018 Jul; 7(7):3311-3320. PubMed ID: 29845747 [TBL] [Abstract][Full Text] [Related]
19. LncRNA SNHG16 promotes colorectal cancer cell proliferation, migration, and epithelial-mesenchymal transition through miR-124-3p/MCP-1. Chen ZY; Wang XY; Yang YM; Wu MH; Yang L; Jiang DT; Cai H; Peng Y Gene Ther; 2022 Apr; 29(3-4):193-205. PubMed ID: 32859986 [TBL] [Abstract][Full Text] [Related]
20. lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p. Zhang Z; Li M; Zhang Z Onco Targets Ther; 2020; 13():1343-1354. PubMed ID: 32104001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]